Oluyemi Okupe Sells 23,584 Shares of Hims & Hers Health (NYSE:HIMS) Stock

Key Points

• Oluyemi Okupe, CFO of Hims & Hers Health, sold 23,584 shares for approximately $1.36 million, reducing his total holdings by 18.28% to 105,400 shares.
• The company's recent stock performance showed a decline, trading at $53.31 after a drop of $2.69, with a market cap of $12.05 billion and a PE ratio of 66.64.
• Hims & Hers Health reported Q2 earnings of $0.17 per share, slightly missing estimates, with a year-over-year revenue increase of 72.6% despite challenging market conditions.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) CFO Oluyemi Okupe sold 23,584 shares of the company's stock in a transaction that occurred on Monday, September 22nd. The shares were sold at an average price of $57.74, for a total value of $1,361,740.16. Following the completion of the transaction, the chief financial officer directly owned 105,400 shares in the company, valued at $6,085,796. The trade was a 18.28% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Oluyemi Okupe also recently made the following trade(s):

• On Monday, September 15th, Oluyemi Okupe sold 145,000 shares of Hims & Hers Health stock. The shares were sold at an average price of $55.35, for a total value of $8,025,750.00.
• On Tuesday, August 26th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The shares were sold at an average price of $43.69, for a total value of $505,973.89.
• On Monday, July 14th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The stock was sold at an average price of $47.70, for a total value of $552,413.70.
• On Monday, July 7th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The shares were sold at an average price of $46.67, for a total transaction of $540,485.27.

Hims & Hers Health Stock Performance

NYSE:HIMS traded down $2.69 during mid-day trading on Wednesday, reaching $53.31. 23,207,860 shares of the company's stock were exchanged, compared to its average volume of 33,019,473. The business's fifty day simple moving average is $50.94 and its two-hundred day simple moving average is $45.99. Hims & Hers Health, Inc. has a one year low of $16.05 and a one year high of $72.98. The firm has a market capitalization of $12.05 billion, a PE ratio of 66.64, a price-to-earnings-growth ratio of 3.90 and a beta of 2.14. The company has a debt-to-equity ratio of 1.72, a quick ratio of 4.46 and a current ratio of 4.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). The business had revenue of $544.83 million during the quarter, compared to analyst estimates of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The firm's quarterly revenue was up 72.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.06 earnings per share. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Institutional Trading of Hims & Hers Health

A number of hedge funds have recently made changes to their positions in the company. Virtus Advisers LLC acquired a new position in shares of Hims & Hers Health in the second quarter valued at approximately $26,000. Quaker Wealth Management LLC acquired a new position in Hims & Hers Health in the 2nd quarter valued at approximately $29,000. Bessemer Group Inc. raised its stake in shares of Hims & Hers Health by 105.8% during the second quarter. Bessemer Group Inc. now owns 607 shares of the company's stock valued at $30,000 after acquiring an additional 312 shares during the last quarter. Skandinaviska Enskilda Banken AB publ lifted its holdings in shares of Hims & Hers Health by 408.2% during the second quarter. Skandinaviska Enskilda Banken AB publ now owns 747 shares of the company's stock worth $37,000 after purchasing an additional 600 shares during the period. Finally, Spire Wealth Management acquired a new position in shares of Hims & Hers Health during the second quarter worth $42,000. 63.52% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Needham & Company LLC reaffirmed a "hold" rating on shares of Hims & Hers Health in a research note on Tuesday, August 5th. Zacks Research lowered shares of Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 19th. Truist Financial dropped their target price on shares of Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating for the company in a research report on Monday, August 18th. Wall Street Zen lowered shares of Hims & Hers Health from a "buy" rating to a "hold" rating in a research report on Monday, July 28th. Finally, UBS Group set a $30.00 price objective on shares of Hims & Hers Health in a research note on Monday, June 23rd. Two analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Reduce" and a consensus price target of $38.92.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.